{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122 Automated Microbiology System"
    ],
    "Submitter Information": "BD Diagnostic Systems Becton, Dickinson and Company",
    "510(k) Number": "K250344",
    "Predicate Device Reference 510(k) Number(s)": [
        "K131331"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "February 6, 2025",
    "Summary Letter Received Date": "February 6, 2025",
    "Submission Date": "February 3, 2025",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [],
    "Specimen Type(s)": [
        "Pure culture isolates of clinically significant bacteria",
        "Yeast and yeast-like organisms"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix\u2122 Automated Microbiology System",
        "BD Phoenix AP Instrument",
        "BD PhoenixSpec nephelometer",
        "BD EpiCenter\u2122 data management system",
        "BD Synapsys\u2122 Informatics Solution"
    ],
    "Method(s)/Technology(ies)": [
        "Broth-based microdilution",
        "Automated growth-based detection",
        "Colorimetric oxidation-reduction"
    ],
    "Methodologies": [
        "Determination of minimal inhibitory concentration (MIC)",
        "Antimicrobial susceptibility testing (AST)",
        "Rapid identification (ID)"
    ],
    "Submission Type(s)": [
        "System",
        "Instrument",
        "Software",
        "Panel"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System using broth microdilution and automated detection for rapid identification and antimicrobial susceptibility testing of clinically significant bacteria",
    "Indications for Use Summary": "Intended for rapid identification and antimicrobial susceptibility testing of clinically significant aerobic and facultative anaerobic Gram-positive and Gram-negative bacteria, as well as rapid identification of yeast and yeast-like organisms from pure culture isolates.",
    "fda_folder": "Microbiology"
}